Outlook Therapeutics (NASDAQ:OTLK) has appointed Lawrence Kenyon, EVP, CFO, and board member, as interim CEO, effective immediately. Russell Trenary has stepped down as the company’s president and CEO.
Mr. Kenyon has served as Outlook’s CFO and secretary since September 2015. He joined the company’s board of directors in August 2018 and previously held the roles of president and CEO from August 2018 to July 2021.
“On behalf of our management team and board, I would like to thank Russ for his dedication and many contributions to the company and wish him the best in his future endeavors,” said Randy Thurman, executive chairman of Outlook.
“We are pleased to have Larry lead Outlook Therapeutics during this transition period. We remain committed to our plans to resubmit the BLA for ONS-5010 in the first quarter of calendar 2025 and to begin sales of LYTENAVA in Europe in the first half of calendar 2025,” Mr. Thurman added.
